Upstream Bio (UPB) Accumulated Expenses (2023 - 2026)

Upstream Bio's Accumulated Expenses history runs 4 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 153.14% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 153.14% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 55.43% from the prior year.
• Accumulated Expenses eased to $2.2 million in Q1 2026 per UPB's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $4.2 million in Q4 2025 and bottomed at $875000.0 in Q1 2025.
• The 4-year median for Accumulated Expenses is $2.2 million (2023), against an average of $2.4 million.
• Across the five-year window, Accumulated Expenses grew 24.4% in 2024 and soared 153.14% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $2.2 million in 2023, then increased by 24.4% to $2.7 million in 2024, then jumped by 55.43% to $4.2 million in 2025, then tumbled by 47.16% to $2.2 million in 2026.
• Per Business Quant, the three latest UPB Accumulated Expenses figures stand at $2.2 million (Q1 2026), $4.2 million (Q4 2025), and $3.0 million (Q3 2025).